was founded as a spin off of the recombinant antibody development company Yumab GmbH.
CORAT develops phage-display derived fully human antibodies into passive vaccines to treat and to protect against COVID-19.
CORAT uses antibody phage display technologies and molecules co-developed with Braunschweig University of Technology.
NEWS: 28.Sept.2020 – CORAT won the Innovation Award of the State of Lower Saxony. Björn Thümler, Minister of Science; Prof. Michael Hust, University of Braunschweig; Dr. Bernd Althusmann, Minister for Economy, Dr. Thomas Schirrmann, CEO of Yumab GmbH, Prof. Josef von Helden, Director of the Board of Innovation Nework Niedersachsen (from the left).
what we do
CORAT Therapeutics develops a passive vaccination immunotherapy against COVID-19 employing novel fully human monoclonal antibodies very efficiently neutralising SARS-CoV2.
Our goal is to realise our vision of an immunotherapeutic remedy for acute COVID-19 as fast as possible. If successful, our drug candidate may also be applied in a prophylactic scheme for the immediate protection of medical care personnel, impaired patients or risk groups.
Towards our goals, a large set of more than 750 different fully human monoclonal antibodies recognising SARS-CoV2 Spike (S) protein has already been isolated by antibody phage display from human antibody gene libraries obtained from healthy donors and convalescent COVID-19 patients. These antibody candidates underwent a fast track development process to identify the lead molecules with the optimal drug features for a passive vaccine. Innovative and state of the art methods and our large network of scientific experts, supporters and competent contract companies currently work together to manufacture the drug. We aim to achieve first-in-man studies in much shorter time than ever done before due to the current high burden of the disease, while keeping all necessary safety and quality requirements for medical use substances in accordance with the respective authorities.
How our passive vaccines work: antibodies can directly block SARS-CoV-2 infection by preventing the attachment of the virus to the human cells
how CORAT antibodies protect
Recombinant human virus-neutralizing antibodies are the active components of our immunotherapy concept (also named „passive vaccine“). Antibodies (immunogobulins, IgG) are molecules made by our own body to protect us against infections.
The CORAT antibody will neutralise SARS-CoV2 directly after injection and so provide protection in exactly the same way like the antibodies of our own body do once we generated them due to an infection or after a vaccination. The CORAT antibody stops the virus by inhibiting its capacity to enter our cells, so immediately protecting the patients until their own immune system had enough time to their own antibodies. CORAT Therapeutics‘ neutralising antibodies are expected to be very well tolerated, because they are fully human proteins like the antibodies we have in our body every day anyway. Due to the long serum half time, a CORAT antibody could be given before infection to protect risk populations or medical care personnel, or after an infection with immediate antiviral effect and long protection until the body had the time to produce enough of its own IgG.
write us an email
CORAT Therapeutics Gmbh
Phone +49 1522 4047488
Commercial Registry: HRB 208500, Registergericht Braunschweig
V.i.S.d.P.: Dr. Andreas Herrmann